Pfizer/Celltrion received FDA approval for Inflectra®, biosimilar infliximab.
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Bioblast Editor | Apr 05, 2016
Pfizer/Celltrion received FDA approval for Inflectra®, biosimilar infliximab.
By Bioblast Editor | Apr 01, 2016
EU’s CHMP gives green light for Flixabi®, Samsung Bioepis’ biosimilar infliximab.
By Bioblast Editor | Mar 24, 2016
Samsung Bioepis files suit in the UK to remove Abbvie patents regarding adalimumab.
By Bioblast Editor | Feb 11, 2016
EMA accepts Sandoz’s filing for Zioxtenzo, biosimilar pegfilgrastim.
By Bioblast Editor | Jan 17, 2016
EMA approves Benepali®, biosimilar etanercept (SB4) for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and plaque psoriasis. CHMP positive opinion was announced on 20 Nov 2015. Samsung says it developed, tested and had its Benepali® app...
By Bioblast Editor | Jan 11, 2016
MabTech announces successful Chinese Ph III clinical trials for Sorrento’s “biosimilar/biobetter” cetuximab STI-001, and infliximab STI-002.
By Bioblast Editor | Jan 11, 2016
MabTech announces successful Chinese Ph III clinical trials for Sorrento’s “biosimilar/biobetter” cetuximab STI-001, and infliximab STI-002.
By Bioblast Editor | Dec 07, 2015
Health Canada confirms Authorisation of Filgrastim biosimilar Grastofil®.
By Bioblast Editor | Dec 01, 2015
Hospira’s biosimilar infliximab becomes the first biosimilar infliximab to be PBS listed in Australia.
By Bioblast Editor | Nov 25, 2015
Amgen submits BLA under s351(k) pathway for ABP 501 (proposed adalimumab biosimilar).
SUBSCRIBE TO PEARCE IP